Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Page standards status: Informative |
{
"resourceType" : "Composition",
"id" : "236951",
"meta" : {
"versionId" : "111",
"lastUpdated" : "2026-06-08T13:51:22.449Z",
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/summary-of-findings"
]
},
"language" : "en",
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Composition 236951</b></p><a name=\"236951\"> </a><a name=\"hc236951\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 111; Last updated: 2026-06-08 13:51:22+0000</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-summary-of-findings.html\">SummaryOfFindings</a></p></div><p><b>Artifact Description</b>: </p><div><p>Example of SummaryOfFindings Profile for Evidence Based Medicine on FHIR Implementation Guide</p>\n</div><p><b>ArtifactPublicationStatus</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-status-type active}\">Active</span></p><p><b>url</b>: <a href=\"https://fevir.net/resources/Composition/236951\">https://fevir.net/resources/Composition/236951</a></p><p><b>identifier</b>: FEvIR Object Identifier/236951, FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-summary-of-findings-85394-85798</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 SummaryOfFindings}\">Summary of Findings</span></p><p><b>date</b>: 2026-06-08 13:51:22+0000</p><p><b>author</b>: Qiukui Hao</p><p><b>title</b>: SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes</p><p><b>custodian</b>: <a href=\"Organization-118079.html\">Computable Publishing LLC</a></p><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Part Of</p><p><b>target</b>: MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Part Of</p><p><b>target</b>: ComparativeEvidenceSynthesisReport: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-comparative-evidence-report-85394-85798)</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cite As</p><p><b>target</b>: </p><div><p>SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Composition Resource]. Contributors: Qiukui Hao [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236951. Revised 2026-06-08. Available at: https://fevir.net/resources/Composition/236951. Computable resource at: https://fevir.net/resources/Composition/236951#json.</p>\n</div></blockquote></div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-description",
"valueMarkdown" : "Example of SummaryOfFindings Profile for Evidence Based Medicine on FHIR Implementation Guide"
},
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
"code" : "active",
"display" : "Active"
}
]
}
}
],
"url" : "https://fevir.net/resources/Composition/236951",
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "https://fevir.net/FOI",
"value" : "236951",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
{
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-summary-of-findings-85394-85798",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "SummaryOfFindings",
"display" : "SummaryOfFindings"
}
],
"text" : "Summary of Findings"
},
"date" : "2026-06-08T13:51:22.449Z",
"author" : [
{
"display" : "Qiukui Hao"
}
],
"title" : "SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes",
"custodian" : {
🔗 "reference" : "Organization/118079",
"type" : "Organization",
"display" : "Computable Publishing LLC"
},
"relatesTo" : [
{
"type" : "part-of",
"targetReference" : {
"type" : "Composition",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-conversion-report",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"
}
},
{
"type" : "part-of",
"targetReference" : {
"type" : "Composition",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-comparative-evidence-report-85394-85798",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "ComparativeEvidenceSynthesisReport: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
},
{
"type" : "cite-as",
"targetMarkdown" : "SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Composition Resource]. Contributors: Qiukui Hao [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236951. Revised 2026-06-08. Available at: https://fevir.net/resources/Composition/236951. Computable resource at: https://fevir.net/resources/Composition/236951#json."
}
],
"section" : [
{
"title" : "Column Headers",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "column-headers",
"display" : "Column Headers"
}
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No narrative text.]</p></div>"
},
"section" : [
{
"title" : "Outcome Measure",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Outcome</p></div>"
}
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Sample Size</p></div>"
}
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Result Without Treatment</p></div>"
}
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Result With Treatment (Observed)</p></div>"
}
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Result With Treatment (Calculated)</p></div>"
}
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Effect Estimate</p></div>"
}
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Certainty of Evidence</p></div>"
}
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What this means</p></div>"
}
}
]
},
{
"title" : "Summary of Findings",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings",
"display" : "Summary of Findings"
}
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"section" : [
{
"title" : "All-cause mortality",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings-entry-for-a-single-outcome",
"display" : "Summary of findings entry for a single outcome"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/236953",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313956",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: All-cause mortality"
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>All-cause mortality</p></div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236953",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313956",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: All-cause mortality"
}
]
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>2 studies, 1282 participants</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557343",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>24.1%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557345",
"type" : "Evidence",
"display" : "MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>21.8%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557344",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-intervention-idence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>21.84%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557345",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparator-onidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes"
},
{
"reference" : "Evidence/557343",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference -2.3% (CI95 -4.0% to -0.4%); OR 0.88 (CI95 0.79 to 0.98)</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557343",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Moderate certainty -- Due to serious imprecision</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557343",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>SGLT2 inhibitors probably reduce the risk of all cause mortality compared with GLP-1 receptor agonists.</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557343",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title" : "Cardiovascular mortality",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings-entry-for-a-single-outcome",
"display" : "Summary of findings entry for a single outcome"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/236956",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313957",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Cardiovascular mortality"
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Cardiovascular mortality</p></div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236956",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313957",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Cardiovascular mortality"
}
]
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>1 studies, 463 participants</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557346",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>15.7%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557348",
"type" : "Evidence",
"display" : "MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>15.2%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557347",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-intervention-idence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>15.17%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557348",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparator-onidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes"
},
{
"reference" : "Evidence/557346",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference -0.5% (CI95 -2.2% to 1.2%); OR 0.96 (CI95 0.84 to 1.09)</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557346",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Moderate certainty -- Due to serious imprecision</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557346",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>There probably be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists.</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557346",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title" : "Nonfatal myocardial infarction",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings-entry-for-a-single-outcome",
"display" : "Summary of findings entry for a single outcome"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/236959",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313958",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Nonfatal myocardial infarction"
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Nonfatal myocardial infarction</p></div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236959",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313958",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Nonfatal myocardial infarction"
}
]
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>1 studies, 463 participants</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557349",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>17.7%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557351",
"type" : "Evidence",
"display" : "MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>17%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557350",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-intervention-idence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>16.97%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557351",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparator-onidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes"
},
{
"reference" : "Evidence/557349",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference -0.7% (CI95 -2.4% to 1.1%); OR 0.95 (CI95 0.84 to 1.08)</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557349",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Moderate certainty -- Due to serious imprecision</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557349",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of nonfatal myocardial infarction.</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557349",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title" : "Nonfatal stroke",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings-entry-for-a-single-outcome",
"display" : "Summary of findings entry for a single outcome"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/236962",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313959",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Nonfatal stroke"
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Nonfatal stroke</p></div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236962",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313959",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Nonfatal stroke"
}
]
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>2 studies, 1282 participants</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557352",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>16.5%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557354",
"type" : "Evidence",
"display" : "MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>19.2%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557353",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-intervention-idence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>19.17%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557354",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparator-onidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes"
},
{
"reference" : "Evidence/557352",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference 2.7% (CI95 0.4% to 5.3%); OR 1.2 (CI95 1.03 to 1.41)</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557352",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Moderate certainty -- Due to serious imprecision</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557352",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p> SGLT2 inhibitors probably increase the risk of nonfatal stroke compared with GLP-1 receptor agonists.</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557352",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title" : "End-stage kidney disease",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings-entry-for-a-single-outcome",
"display" : "Summary of findings entry for a single outcome"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/236965",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313960",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: End-stage kidney disease"
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>End-stage kidney disease</p></div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236965",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313960",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: End-stage kidney disease"
}
]
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>1 studies, 463 participants</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557355",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>11.9%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557357",
"type" : "Evidence",
"display" : "MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>10.9%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557356",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-intervention-idence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>10.95%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557357",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparator-onidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes"
},
{
"reference" : "Evidence/557355",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference -1.0% (CI95 -3.4% to 2.0%); OR 0.91 (CI95 0.69 to 1.2)</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557355",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Moderate certainty -- Due to serious imprecision</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557355",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>There probably be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists.</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557355",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title" : "Heart failure",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings-entry-for-a-single-outcome",
"display" : "Summary of findings entry for a single outcome"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/236968",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313961",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Heart failure"
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Heart failure</p></div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236968",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313961",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Heart failure"
}
]
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No sample size data.]</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557358",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>22.4%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557360",
"type" : "Evidence",
"display" : "MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>17.6%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557359",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-intervention-idence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>17.6%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557360",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparator-onidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes"
},
{
"reference" : "Evidence/557358",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference -4.8% (CI95 -6.6% to -2.7%); OR 0.74 (CI95 0.65 to 0.85)</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557358",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>High certainty</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557358",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>SGLT2 inhibitors reduce the risk of heart failure compared with GLP-1 receptor agonists.</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557358",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title" : "Diabetic ketoacidosis",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings-entry-for-a-single-outcome",
"display" : "Summary of findings entry for a single outcome"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/236971",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313962",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Diabetic ketoacidosis"
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Diabetic ketoacidosis</p></div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236971",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313962",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Diabetic ketoacidosis"
}
]
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>1 studies, 463 participants</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557361",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.1%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557363",
"type" : "Evidence",
"display" : "MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.2%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557362",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-intervention-idence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>0.17%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557363",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparator-onidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes"
},
{
"reference" : "Evidence/557361",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference 0.1% (CI95 0.0% to 0.3%); OR 1.71 (CI95 0.79 to 3.69)</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557361",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>High certainty</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557361",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of diabetic ketoacidosis.</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557361",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title" : "Serious hyperglycaemia",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings-entry-for-a-single-outcome",
"display" : "Summary of findings entry for a single outcome"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/236974",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313963",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Serious hyperglycaemia"
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Serious hyperglycaemia</p></div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236974",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313963",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Serious hyperglycaemia"
}
]
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>1 studies, 463 participants</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557364",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>1%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557366",
"type" : "Evidence",
"display" : "MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>1.5%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557365",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-intervention-idence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>1.47%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557366",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparator-onidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes"
},
{
"reference" : "Evidence/557364",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference 0.5% (CI95 -0.2% to 1.9%); OR 1.48 (CI95 0.75 to 2.93)</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557364",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>High certainty</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557364",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of serious hyperglycaemia.</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557364",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title" : "Genital infection",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings-entry-for-a-single-outcome",
"display" : "Summary of findings entry for a single outcome"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/236977",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313964",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Genital infection"
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Genital infection</p></div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236977",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313964",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Genital infection"
}
]
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>2 studies, 1282 participants</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557367",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>5%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557369",
"type" : "Evidence",
"display" : "MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>20.8%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557368",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-intervention-idence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>20.83%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557369",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparator-onidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes"
},
{
"reference" : "Evidence/557367",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference 15.8% (CI95 6.4% to 29.9%); OR 5.0 (CI95 2.45 to 10.2)</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557367",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>High certainty</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557367",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>SGLT2 inhibitors increase the risk of genital infection compared with GLP-1 receptor agonists.</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557367",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title" : "Severe gastrointestinal events",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings-entry-for-a-single-outcome",
"display" : "Summary of findings entry for a single outcome"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/236980",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313965",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Severe gastrointestinal events"
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Severe gastrointestinal events</p></div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236980",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313965",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Severe gastrointestinal events"
}
]
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>7 studies, 24638 participants</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557370",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>4.4%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557372",
"type" : "Evidence",
"display" : "MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>10.2%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557371",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-intervention-idence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>10.17%</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557372",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparator-onidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes"
},
{
"reference" : "Evidence/557370",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Risk Difference 5.8% (CI95 0.9% to 14.2%); OR 2.46 (CI95 1.22 to 4.97)</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557370",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Very low certainty -- Due to serious inconsistency, Due to very serious indirectness, Due to very serious imprecision</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557370",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>GLP-1 receptor agonists may increase the risk of severe gastrointestinal events compared with SGLT2 inhibitors.</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557370",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-eidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title" : "Health-related quality of life",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings-entry-for-a-single-outcome",
"display" : "Summary of findings entry for a single outcome"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/236983",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-109587",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Health-related quality of life"
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Health-related quality of life</p></div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236983",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-109587",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Health-related quality of life"
}
]
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No sample size data.]</p></div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236984",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>MEAN 51.84 </p></div>"
},
"entry" : [
{
"reference" : "Evidence/557374",
"type" : "Evidence",
"display" : "MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>MEAN 51.91 </p></div>"
},
"entry" : [
{
"reference" : "Evidence/557373",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109587-intervention-oidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[Not a proportion.]</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557374",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparator-onlidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes"
},
{
🔗 "reference" : "Evidence/236984",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>SMD 0.01 (CI95 -0.19 to 0.2 )</p></div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236984",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Low certainty -- Due to very serious imprecision</p></div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236984",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>There may be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on health-related quality of life.</p></div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236984",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title" : "Body weight",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings-entry-for-a-single-outcome",
"display" : "Summary of findings entry for a single outcome"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/236986",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-109588",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Body weight"
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Body weight</p></div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236986",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-109588",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Body weight"
}
]
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>2 studies, 1139 participants</p></div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236987",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>MEAN 86.55 Kg</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557376",
"type" : "Evidence",
"display" : "MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>MEAN 86.08 Kg</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557375",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109588-intervention-oidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[Not a proportion.]</p></div>"
},
"entry" : [
{
"reference" : "Evidence/557376",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparator-onlidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes"
},
{
🔗 "reference" : "Evidence/236987",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>MD -0.47 Kg (CI95 -0.09 Kg to -0.85 Kg)</p></div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236987",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Moderate certainty -- Due to serious inconsistency</p></div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236987",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>SGLT2 inhibitors probably reduce body weight compared with GLP-1 receptor agonists.</p></div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236987",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
}
]
},
{
"title" : "Groups",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "groups",
"display" : "Groups"
}
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No narrative text.]</p></div>"
},
"section" : [
{
"title" : "Total Group",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "population",
"display" : "Population"
}
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Intervention Group",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "intervention-group",
"display" : "Intervention Group"
}
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Comparator Group",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "comparator-group",
"display" : "Comparator Group"
}
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Group Assignment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "GroupAssignment",
"display" : "GroupAssignment"
}
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
}
]
},
{
"title" : "Variables (Measures)",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "variables",
"display" : "Variables"
}
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236953",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313956",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: All-cause mortality"
},
{
🔗 "reference" : "EvidenceVariable/236956",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313957",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Cardiovascular mortality"
},
{
🔗 "reference" : "EvidenceVariable/236959",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313958",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Nonfatal myocardial infarction"
},
{
🔗 "reference" : "EvidenceVariable/236962",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313959",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Nonfatal stroke"
},
{
🔗 "reference" : "EvidenceVariable/236965",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313960",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: End-stage kidney disease"
},
{
🔗 "reference" : "EvidenceVariable/236968",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313961",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Heart failure"
},
{
🔗 "reference" : "EvidenceVariable/236971",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313962",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Diabetic ketoacidosis"
},
{
🔗 "reference" : "EvidenceVariable/236974",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313963",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Serious hyperglycaemia"
},
{
🔗 "reference" : "EvidenceVariable/236977",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313964",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Genital infection"
},
{
🔗 "reference" : "EvidenceVariable/236980",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313965",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Severe gastrointestinal events"
},
{
🔗 "reference" : "EvidenceVariable/236983",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-109587",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Health-related quality of life"
},
{
🔗 "reference" : "EvidenceVariable/236986",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-109588",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Body weight"
}
]
}
]
}
IG © 2024+ HL7 International / Clinical Decision Support.
Package hl7.fhir.uv.ebm#1.0.0-ballot3 based on FHIR 6.0.0-ballot3.
Generated
2026-06-12
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change